A novel approach in the treatment of type 2 diabetes is to harvest the actions of incretin hormones such as glucagon like peptide (GLP)-1 and glucose-dependent insulinotropic peptide (GIP). This evidence concerns the gene GIP and type 2 diabetes mellitus.